The described new type is epigenetically divergent from all other described CNS tumor types and in the vast majority of cases marked by amplification of one of the PLAG-family genes, PLAGL1 or PLAGL2. Despite the initial diagnosis as medulloblastoma, other embryonal tumor, or HGG in more than half of cases, PLAGL-amplified tumors differ both epigenetically and in terms of outcome from these other tumor types. This evidence concerns the gene PLAGL1 and embryonal neoplasm.